Global acceptance of COVID-19 vaccine among persons with diabetes: A systematic review and meta-analysis
Authors' conclusion
The barriers to vaccine acceptance identified in this review, could inform the formulation of health policies and public health interventions that are specifically tailored to address the needs of persons with diabetes.
Study context
- Population
- Persons with diabetes; studies from PubMed, MEDLINE, Embase and CINAHL
- Participants
- 11,292 persons18 studies
- Outcome
- Pooled prevalence of COVID-19 vaccine acceptance
Methodological detailsrandom-effects meta-analysis, subgroup analysis, PRISMA
- Random-effects meta-analysis
- Subgroup analysis
- PRISMA
Pooled result
As reported in the abstract
COVID-19 vaccine acceptance (pooled prevalence)
Pooled prevalence of COVID-19 vaccine acceptance
76.1%
95% CI 66.7%–83.5%
Further pooled results
Pooled prevalence of vaccine acceptance by continent
- Asia
- 68.9% (95% CI 47.8%-84.3%)
- Europe
- 82.1% (95% CI 80.2%-83.8%)
- Range across continents: lowest Asia, highest Europe
Barriers to vaccine acceptance
- Barriers included misinformation, lack of information, mistrust, health concerns and external influences
Original publication
Global acceptance of COVID-19 vaccine among persons with diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. Published 24 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →